Enteromix is a customized mRNA-based cancer treatment. It uses genetic material extracted from the patient’s own tumor to instruct the immune system to recognize and combat cancer cells. According to Economic Times, Russian developers claim that they have integrated artificial intelligence to drastically cut production time from months to just hours. In partnership with the Russian Academy of Sciences, Russia’s National Medical Research Radiological Centre is developing the technology. Even while this strategy is in keeping with worldwide research trends with mRNA cancer treatments, it’s crucial to remember that Enteromix is still in the early stages of development.
Clinical Evidences
There are significant limits to the Enteromix evidence. Only 48 individuals with colorectal cancer were included in the trial, according to Indian Express, when appropriate Phase II trials often require 100–300 participants with a variety of cancer types. In order to validate medical claims, the results must be published in a peer-reviewed scientific journal. The study’s use of a control group for comparison is still up for debate, and the follow-up time was significantly shorter than the two to five years that are normally required by international standards. Because of these serious flaws, the 100% efficacy claim is seriously dubious from a scientific standpoint.
Claims of “100 percent efficiency” in a Phase I trial should be interpreted cautiously, according to Dr. Dhiren Bhatia, a clinical oncologist and former adviser to the WHO’s cancer research division, who spoke to India Today. He pointed out that there were just 48 patients in the Enteromix trial, which is much too few to draw generalizable findings. Furthermore, the results have not been independently verified or subjected to peer review.
Raw data, biomarker analysis, and survival outcomes like progression-free and overall survival measured after 6–12 months are what the scientific community would anticipate, Dr. Bhatia said. Enteromix should be considered an intriguing but unproven intervention rather than a revolutionary cancer cure in the absence of these crucial details.
Results : Complete Immune system
According to Russian officials, 48 individuals with colorectal cancer—one of the most prevalent and fatal types of the disease worldwide—have received the vaccination. Based on first reports:
- Each and every patient exhibited an immunological response, which means that the cancer cells were attacked by their bodies.
- Tumors shrank or stopped developing in 68% to 80% of individuals.
- Since there were no serious adverse effects noted, the vaccination might be safe enough to be used repeatedly.
According to reports, the vaccination was effective even against malignancies that had resisted chemotherapy. Versions of Enteromix are demonstrating early promise against glioblastoma, an aggressive brain cancer, and some advanced melanomas in addition to colorectal cancer, according to Russian experts.
Can Enteromix Enters Early Clinical Use
Enteromix must to be approved by the Russian Ministry of Health before it may be distributed to patients. If approved, it would be a significant scientific and symbolic milestone as the first mRNA-based cancer vaccine to be made available for clinical use worldwide. The Russian government has already indicated that it plans to pay for the vaccine so that patients can get it for free if prices stay high.
Can Cancer Vaccine is Ready To use as Per FMBA Russia?
The head of Russia’s Federal Medical and Biological Agency (FMBA), Veronika Skvortsova, described this strategy as “fundamentally new.” “We are awaiting official approval, but the vaccine is now ready for use.”
How Enteromix Works for Cancer Treatement ?
Cancer is a word that instantly fills our hearts and minds with fear. The pain of chemotherapy, the heavy cost of treatment, and the uncertain future—that’s the story of cancer. But what if I told you this story is about to change? What if I told you that somewhere in the world, a vaccine has been developed that achieved 100% success in its initial trials?
Now, you might be wondering, what’s so special about it? How does it work? Well, remember, the COVID vaccine was made using mRNA technology, and this treatment uses the same mRNA technology.
Let me explain this in simple terms. Our body has an immune system that acts like a bodyguard. It fights off diseases, but cancer cells are really sneaky. They trick the bodyguard, hide inside the body, and start multiplying. So, what does the Entero Mix vaccine do? It trains our immune system, our bodyguard, by showing it pictures and identifying the cancer cells. Using mRNA technology, it sends a message to the body saying, “Hey, this is your enemy. Recognize it and get rid of it.” Once our immune system learns to recognize cancer cells and then goes on to find and destroy them on its own. It’s not like chemotherapy, where both good and bad cells die. It’s more like a surgical strike, targeting only the enemy. Efforts to create a cancer vaccine have been going on for decades, but most haven’t been successful. So, what’s special about Enteromics? Two things. First, it’s fully personalized. That means it’s not a one-size-fits-all formula. It’s made individually for each patient.
Scientist first take a sample of the tumor, analyze its DNA, and then create a custom-made vaccine specifically for that patient’s tumor. Just like a tailor makes clothes to fit your measurements, this vaccine is made according to each patient’s cancer. This makes it much more effective. The other is the mRNA platform. This technology is really fast and adaptable, meaning it can be made quickly and modified for different types of cancer
Which type of Cancer does Enteromix Treat?
Enteromix is primarily being developed to treat colon cancer, while it is also being investigated for glioblastoma and melanoma.
1. Colon Cancer
The large intestine, or colon, is the long tube that helps transport digested food to the rectum and out of your body. This is where colon (colorectal) cancer begins.
Certain growths or polyps in your colon’s inner lining can lead to colon cancer. Precancerous tumors can be identified by screening tests used by healthcare practitioners before they develop into malignant tumors. If left untreated, colon cancer has the potential to spread to other parts of the body. There are fewer deaths from colon cancer as a result of screening tests, early treatment, and novel forms of treatment.
2. Glioblastoma Cancer
One kind of cancer that begins as a proliferation of cells in the brain or spinal cord is called glioblastoma. It can infiltrate and obliterate healthy tissue and grows swiftly. Astrocytes, which nourish nerve cells, are the cells that give rise to glioblastoma.
At any age, glioblastoma can develop. However, older persons are more likely to experience it. Headaches that worsen over time, nausea and vomiting, double or blurred vision, difficulty speaking, altered touch perception, and seizures are some of the symptoms of glioblastoma. Additionally, there might be issues with coordination, balance, and facial or body movements.
3. Melanoma Cancer
One type of skin cancer that begins in the melanocytes is called melanoma. The cells that produce the pigment that gives skin its color are called melanocytes. We refer to the pigment as melanin.
Skin that is frequently exposed to the sun is usually where melanoma first appears. The skin on the arms, back, face, and legs is included in this. In the eyes, melanoma can also develop. In rare cases, it may occur inside the body, like in the throat or nose.
How much Cost of Enteromix Vaccine?
According to reports, each dose of the Enteromix cancer vaccine costs over 3 lakh rubles (300,000 rubles) in Russia. This sum is equivalent to about $3,000 USD or ₹2.7 lakh in Indian rupees. Exchange rates may affect the final cost, and Russian officials have hinted that once the vaccine is completely licensed, it may eventually be provided to residents for free.
Conclusion
The Russian-developed experimental mRNA-based cancer vaccine Enteromix was first intended to prevent colon cancer, but it is also being investigated for glioblastoma and melanoma. Peer-reviewed data and complete regulatory clearances are still awaited, although preliminary research on animals and small humans points to safety and possible tumor-shrinking effects. Essentially, Enteromix exhibits potential, but its efficacy and accessibility have not yet been verified due to its early clinical research stages.